Biogen (BIIB) Partners With Alloy Therapeutics on Antisense Drug Platform

Key Takeaways

• Biogen has entered into a multi-target partnership with Alloy Therapeutics to leverage Alloy’s AntiClastic ASO technology for developing antisense therapeutics.
• Financial terms include upfront compensation for Alloy, along with potential milestone-based payments and tiered royalty structures.
• The partnership builds on an existing relationship dating back to 2020, which initially centered on antibody-based therapies.
• RBC Capital reduced Biogen’s price target from $233 to $213 while maintaining its Outperform recommendation.
• Wall Street analysts have established a consensus price target of $210.30 for BIIB with an overweight rating.

Biogen has formalized a strategic partnership with Alloy Therapeutics, securing rights to utilize Alloy’s proprietary AntiClastic antisense oligonucleotide (ASO) technology platform for developing therapies targeting several yet-to-be-disclosed disease areas.

Biogen Inc., BIIB

Under the terms of the arrangement, Alloy Therapeutics will collect an initial payment, with opportunities to earn additional compensation through development and commercial milestones, plus royalty payments tied to any successfully marketed products.

While the two biotechnology firms have maintained a collaborative relationship since 2020, their previous work concentrated on antibody-based treatment development. This latest agreement marks a strategic shift toward genetic medicine applications.

Biogen brings substantial experience to ASO drug development. The company’s Spinraza, approved for treating spinal muscular atrophy, represents one of the commercial success stories in antisense therapy. This new collaboration aims to expand that expertise through Alloy’s technology platform.

The collaboration will prioritize three key objectives for Alloy’s platform: increasing therapeutic potency, reducing immunogenic responses, and improving targeted tissue delivery.

Alloy’s Expanding Partnership Portfolio

Headquartered in Waltham, Massachusetts, Alloy has established a business model centered on collaborative drug discovery and development with biopharmaceutical companies. Since launching in 2017, the company has executed approximately 200 partnership agreements, with over 100 producing licensed therapeutic candidates.

The platform has contributed to 22 drug candidates that have advanced into clinical testing. In 2024, Sanofi entered into an agreement potentially worth up to $400 million to access this same ASO technology for developing central nervous system treatments.

Christian Cobaugh, who leads Alloy’s Genetic Medicine Division as CEO, indicated the Biogen collaboration will enable the company to expand its involvement beyond initial discovery phases into later-stage development activities.

Alloy differentiates itself from typical platform biotechnology companies by focusing exclusively on partnerships rather than developing an internal proprietary pipeline.

Wall Street’s Perspective on Biogen

From an analyst perspective, RBC Capital Markets revised its price target for BIIB downward to $213 from a previous $233 on April 7, though the firm maintained its Outperform rating.

According to FactSet’s analyst consensus data, the mean price target for Biogen shares currently sits at $210.30, accompanied by an overweight rating across the Street.

BIIB shares declined 2.82% on the trading day when the partnership was publicly announced.

The post Biogen (BIIB) Partners With Alloy Therapeutics on Antisense Drug Platform appeared first on Blockonomi.